null
...
US health chiefs accuse AstraZeneca of providing 'outdated' information from its vaccine trial - when it claimed the shot was 79% effective - in a bid to get approval in America
US health chiefs have accused AstraZeneca of sending 'outdated information' as part of an application to get its Covid vaccine approved for use on Americans.
The drug giant, which is manufacturing Oxford University's jab, revealed yesterday that a US-specific trial found the vaccine prevented 100 per cent of hospital admissions and deaths from Covid, along with 79 per cent of all symptomatic infections. It said it hoped to get a licence from drug regulators within weeks.
But the National Institute of Allergy and Infectious Diseases (NIAID) – a health authority headed up by Dr Anthony Fauci, the country's top infectious disease expert – said last night that the information it had sent over 'provided an incomplete view of the efficacy data'.
The NIAID, a division of the US National Institutes of Health, made the 'unprecedented' call for more data in public — discussions usually happen behind closed doors. It asked the company to provide up-to-date figures 'as quickly as possible' but did not offer its own estimate of how well the vaccine works.
The hiccup is latest in a string of PR disasters for AstraZeneca, which has faced constant criticism over its jab with European officials first claiming it didn't work on older people and later that it caused blood clots – neither of which turned out to be true. UK and EU officials are now rowing over supplies.
Real-world data proves that the vaccine is protecting people against Covid in the UK, which has given the jab to over 13million people since it was approved in January. It means any updated figures are unlikely to change the regulator's decision but must be examined thoroughly.
Experts reacting to the NIAID's statement released last night described it as 'unusual' and said airing grievances in the public domain was 'unprecedented'. They criticised AstraZeneca for 'confusing' officials with the way it was sending its data.
AstraZeneca is accused of providing 'outdated' information from its US vaccine trial | Daily Mail Online
- The National Institute of Allergy and Infectious Diseases accused AstraZeneca of using outdated trial data
- The organization made the statement hours after AstraZeneca claimed its vaccine was 100% effective
- The latest trial of AstraZeneca's Covid jab was done on 32,000 people in US, Chile and Peru
- Nobody who received the real vaccine developed severe COVID-19 or died of it, the company said
- No severe side effects nor increased risk of blood clots were reported in people in the study, it claimed
- Research was carried out because US wanted a US-based trial before approving it for use on its own citizens
US health chiefs have accused AstraZeneca of sending 'outdated information' as part of an application to get its Covid vaccine approved for use on Americans.
The drug giant, which is manufacturing Oxford University's jab, revealed yesterday that a US-specific trial found the vaccine prevented 100 per cent of hospital admissions and deaths from Covid, along with 79 per cent of all symptomatic infections. It said it hoped to get a licence from drug regulators within weeks.
But the National Institute of Allergy and Infectious Diseases (NIAID) – a health authority headed up by Dr Anthony Fauci, the country's top infectious disease expert – said last night that the information it had sent over 'provided an incomplete view of the efficacy data'.
The NIAID, a division of the US National Institutes of Health, made the 'unprecedented' call for more data in public — discussions usually happen behind closed doors. It asked the company to provide up-to-date figures 'as quickly as possible' but did not offer its own estimate of how well the vaccine works.
The hiccup is latest in a string of PR disasters for AstraZeneca, which has faced constant criticism over its jab with European officials first claiming it didn't work on older people and later that it caused blood clots – neither of which turned out to be true. UK and EU officials are now rowing over supplies.
Real-world data proves that the vaccine is protecting people against Covid in the UK, which has given the jab to over 13million people since it was approved in January. It means any updated figures are unlikely to change the regulator's decision but must be examined thoroughly.
Experts reacting to the NIAID's statement released last night described it as 'unusual' and said airing grievances in the public domain was 'unprecedented'. They criticised AstraZeneca for 'confusing' officials with the way it was sending its data.
AstraZeneca is accused of providing 'outdated' information from its US vaccine trial | Daily Mail Online
take a look at (perth , western australias cases the past 12 months) for reference
